ALX Oncology Holdings Inc.
AI Valuation
AI-generated fair value estimate for this company.
AI Fair Value
$1.64
Market Price
$1.24
Undervalued By
24.4%
Method: Risk-adjusted NPV: $127.19M net cash plus an estimated $100M risk-adjusted pipeline value for the evorpacept (CD47-blocking antibody) program and broader oncology pipeline, reflecting a moderate probability of eventual approval/partnership value given later-stage trial data; total ~$227.19M; 138.28M shares.
Reasoning: ALX Oncology is a pre-revenue clinical-stage oncology biotech, so a conventional FCF DCF is not meaningful; valuing it as net cash plus a probability-weighted pipeline NPV is the standard approach for clinical-stage biopharma, and the sizeable net cash position provides a solid valuation floor.